Background
Methods
Subjects, ethics statement and NGS analysis
Clinical evaluations
Results
Genetic analyses
Nucleotide change | Amino acid change | Mutation type | Exon/intron | Patients | ACMG category | References |
---|---|---|---|---|---|---|
c.1399C>G | p.Pro467Ala | Missense | E13 | F1-1, F3-1 | P | |
c.272G>A | p.Arg91Gln | Missense | E4 | F2-1 | P | |
c.271C>T | p.Arg91Trp | Missense | E4 | F2-1, F16-1 | P | |
c.1338G>T | p.Arg446Ser | Missense | E12 | F5-1, F7-1, F7-2 | P | |
c.1543C>T | p.Arg515Trp | Missense | E14 | F6-1, F6-2 | P | |
c.1444G>A | p.Asp482Asn | Missense | E13 | F6-1, F6-2, F17-1 | LP | Novel |
c.1255C>T | p.Pro419Ser | Missense | E12 | F8-1 | VUS | Novel |
c.202C>T | p.His68Tyr | Missense | E3 | F8-1 | P | |
c.1590C>A | p.Phe530Leu | Missense | E14 | F9-1 | P | |
c.997G>C | p.Gly333Arg | Missense | E9 | F10-1 | P | [25] |
c.334T>A | p.Cys112Ser | Missense | E4 | F10-1 | VUS | Novel |
c.131G>A | p.Arg44Gln | Missense | E3 | F12-1 | P | |
c.200T>G | p.Leu67Arg | Missense | E3 | F13-1 | P | |
c.1304A>G | p.Tyr435Cys | Missense | E12 | F13-1 | P | [29] |
c.1039C>T | p.Arg347Cys | Missense | E10 | F14-1 | VUS | Novel |
c.1078G>C | p.Ala360Pro | Missense | E10 | F14-1 | LP | [30] |
c.493C>T | p.Gln165* | Nonsense | E5 | F4-1, F4-2 | P | [4] |
c.1380G>A | p.Trp460* | Nonsense | E13 | F15-1 | P | [31] |
c.94+2T>A | - | Splicing | I2 | F1-1 | LP | Novel |
c.998+1G>A | - | Splicing | I10 | F3-1 | P | [13] |
c.354-2A>G | - | Splicing | I5 | F7-1, F7-2 | LP | Novel |
c.858+1del | - | Splicing | I9 | F9-1, F12-1 | P | [8] |
c.376del | p.Val126fs*1 | Frameshift | EX5 | F16-1 | LP | Novel |
c.806_809delinsTGGAGCCATGAAG | p.SerLeu269MetGluProTer | Frameshift | EX8 | F17-1 | P | Novel |
c.837del | p.Phe279Leufs*46 | Frameshift | EX8 | F11-1 | LP | Novel |
c.886del | p.Arg296fs | Frameshift | EX9 | F15-1 | LP | Novel |
Phenotypic characterization
Patients | Age (years) /sex | BCVA LogMAR R/L | Refraction R/L | Age at disease presentation (years) | ERG | Fundus | Others | Diagnosis |
---|---|---|---|---|---|---|---|---|
F1-1 | 12/F | 0/0.05 | + 0.5/ + 0.75 | Congenital | Undetectable rod ERG, subnormal cone ERG | a | No | FAP |
F2-1 | 6/M | 0.60/0.82 | − 0.5/− 2.0 | Congenital | Extinct | a, b | Nystagmus | LCA 2 |
F3-1 | 7/M | 0.40/0.40 | − 4.0/− 3.75 | Congenital | Extinct | N | Nystagmus | LCA 2 |
F4-1 | 15/M | 0.52/0.52 | − 3.5/− 3.0 | Congenital | Extinct | a, b | Nystagmus | LCA 2 |
F4-2 | 3/F | 1.00/1.00 | + 0.5/ + 0.75 | Congenital | Extinct | N | Nystagmus | LCA 2 |
F5-1 | 9/F | 1.30/0.70 | + 4.5/ + 4.5 | Congenital | Extinct | a | Nystagmus | LCA 2 |
F6-1 | 10/M | 0.22/0.40 | − / + 0.5 | 3 | Profoundly attenuated rod and cone ERGs | N | No | RP 20 |
F6-2 | 9/F | 0.40/0.40 | − / + 0.25 | 3 | Profoundly attenuated rod and cone ERGs | a | No | RP 20 |
F7-1 | 29/M | 1.00/3.00 | – | Congenital | Extinct | b | Nystagmus | LCA 2 |
F7-2 | 31/M | 1.3/1.3 | – | Congenital | Extinct | b | Nystagmus | LCA 2 |
F8-1 | 7/F | 1.00/0.13 | + 1.5/ + 2.25 | Congenital | Extinct | a | Nystagmus | LCA 2 |
F9-1 | 11/M | 0.52/0.40 | − 0.5/− 0.5 | Congenital | Profoundly attenuated rod and cone ERGs | a | No | RP 20 |
F10-1 | 49/F | 3.00/3.00 | – | Congenital | Extinct | b | Nystagmus | LCA 2 |
F11-1 | 20/M | 1.00/1.00 | − 2.25/− 1.75 | Congenital | Profoundly attenuated rod and cone ERGs | N | Nystagmus | LCA 2 |
F12-1 | 31/F | 1.00/1.00 | − 1.0/− 1.25 | Congenital | Extinct | b | Nystagmus | LCA 2 |
F13-1 | 9/F | 0.52/0.40 | + 2.5/ + 2.25 | Congenital | Extinct | N | Nystagmus, oculo-digital sign | LCA 2 |
F14-1 | 5/F | 0.60/0.70 | + 2.25/ + 3.0 | Congenital | Extinct | N | Nystagmus, esotropia | LCA 2 |
F15-1 | 5/M | 0.82/1.00 | + 2.0/ + 2.25 | Congenital | Extinct | N | Nystagmus | LCA 2 |
F16-1 | 30/M | 2.00/2.00 | − /− | Congenital | Extinct | N | Nystagmus | LCA 2 |
F17-1 | 30/F | 0.30/0.40 | -4.0/-4.5 | Congenital | Profoundly attenuated rod and cone ERGs | N | No | RP 20 |